RA Capital Management 13F holdings, Q2 2021
Holdings as of June 30, 2021 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 92 US equity positions worth $6.2bn in its Q2 2021 13F filing. The largest position was ASND at 14.4% of the reported book, followed by NVAX and FORMA THERAPEUTICS HLDGS INC. Against the Q1 2021 filing, it opened 9 new positions, added to 6 and reduced 3 among the top 50 holdings.
What did RA Capital Management own in Q2 2021? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2021 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | Healthcare | 14.4% | $895.4m | 6,806,341 | 6% | added |
| 2 | NVAX NOVAVAX INC | Healthcare | 8.7% | $543.5m | 2,559,918 | -15% | reduced |
| 3 | FORMA THERAPEUTICS HLDGS INC | 3.6% | $224.3m | 9,011,651 | 0% | held | |
| 4 | JANX JANUX THERAPEUTICS INC | Healthcare | 3.5% | $216.3m | 8,670,644 | – | new |
| 5 | VOR VOR BIOPHARMA INC | 3.3% | $207.4m | 11,120,973 | 0% | held | |
| 6 | AEROVATE THERAPEUTICS INC | 3.0% | $188.7m | 8,263,982 | – | new | |
| 7 | NKTX NKARTA INC | Healthcare | 2.9% | $177.6m | 5,605,129 | 0% | held |
| 8 | MGNX MACROGENICS INC | Healthcare | 2.6% | $159.6m | 5,943,594 | 20% | added |
| 9 | CNTB CONNECT BIOPHARMA HLDGS LTD | 2.2% | $136.5m | 6,991,003 | 134% | added | |
| 10 | TGTX TG THERAPEUTICS INC | Healthcare | 2.1% | $129.7m | 3,342,743 | -28% | reduced |
| 11 | IMMUNOGEN INC | 1.9% | $121.4m | 18,417,458 | 0% | held | |
| 12 | AVIR ATEA PHARMACEUTICALS INC | Healthcare | 1.9% | $115.3m | 5,368,451 | 0% | held |
| 13 | ITEOS THERAPEUTICS INC | 1.8% | $113.3m | 4,417,259 | 0% | held | |
| 14 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 1.8% | $113.1m | 4,965,588 | – | new | |
| 15 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.8% | $111.7m | 1,655,447 | 0% | held |
| 16 | PHAT PHATHOM PHARMACEUTICALS INC | 1.7% | $105.4m | 3,115,008 | 0% | held | |
| 17 | TIL INSTIL BIO INC | 1.5% | $94.1m | 4,870,793 | 0% | held | |
| 18 | RCKT ROCKET PHARMACEUTICALS INC COM | Healthcare | 1.5% | $93.3m | 2,107,149 | 0% | held |
| 19 | 89BIO INC | 1.5% | $92.9m | 4,965,769 | 5% | added | |
| 20 | ZOGENIX INC | 1.5% | $91.3m | 5,283,976 | 0% | held | |
| 21 | PCVX VAXCYTE INC | Healthcare | 1.4% | $87.0m | 3,865,808 | 0% | held |
| 22 | KINNATE BIOPHARMA INC | 1.3% | $83.6m | 3,593,052 | 0% | held | |
| 23 | GRAPHITE BIO INC | 1.3% | $82.9m | 2,698,369 | – | new | |
| 24 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 1.3% | $81.9m | 5,614,428 | 0% | held |
| 25 | HOWL WEREWOLF THERAPEUTICS INC | 1.2% | $74.8m | 4,291,881 | – | new | |
| 26 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 1.1% | $71.1m | 4,871,067 | 0% | held |
| 27 | CYTEIR THERAPEUTICS INC | 1.1% | $69.5m | 3,247,117 | – | new | |
| 28 | GHRS GH RESEARCH PLC | 1.0% | $64.7m | 2,978,955 | – | new | |
| 29 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 1.0% | $60.2m | 2,150,404 | 0% | held |
| 30 | DYN DYNE THERAPEUTICS INC | Healthcare | 0.9% | $59.0m | 2,805,045 | 0% | held |
| 31 | PMVP PMV PHARMACEUTICALS INC | 0.9% | $58.4m | 1,710,265 | 0% | held | |
| 32 | KALA PHARMACEUTICALS INC | 0.9% | $57.6m | 10,874,613 | 0% | held | |
| 33 | CRIS CURIS INC | Healthcare | 0.9% | $57.6m | 7,140,091 | 0% | held |
| 34 | CEREVEL THERAPEUTICS HLDNG INC | 0.9% | $56.4m | 2,200,000 | 0% | held | |
| 35 | EWTX EDGEWISE THERAPEUTICS INC | 0.9% | $55.7m | 2,613,623 | 0% | held | |
| 36 | ORCHARD THERAPEUTICS PLC | 0.9% | $54.1m | 12,315,213 | 0% | held | |
| 37 | SPRY SILVERBACK THERAPEUTICS INC | Healthcare | 0.9% | $53.8m | 1,742,186 | 0% | held |
| 38 | VERVE THERAPEUTICS INC | 0.9% | $53.0m | 880,284 | – | new | |
| 39 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.8% | $52.1m | 1,377,569 | 0% | held |
| 40 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 0.8% | $51.8m | 7,775,207 | 0% | held |
| 41 | TRILLIUM THERAPEUTICS INC | 0.8% | $51.3m | 5,290,481 | 0% | held | |
| 42 | ACHILLES THERAPEUTICS PLC | 0.8% | $49.1m | 5,014,687 | 261% | added | |
| 43 | CHEMOCENTRYX INC | 0.8% | $46.8m | 3,496,639 | -2% | reduced | |
| 44 | 4XC1 KALVISTA PHARMACEUTICALS INC | 0.7% | $46.3m | 1,930,322 | 452% | added | |
| 45 | ARDX ARDELYX INC | Healthcare | 0.7% | $46.1m | 6,077,294 | 0% | held |
| 46 | SLDB SOLID BIOSCIENCES INC | 0.7% | $45.3m | 12,367,873 | 0% | held | |
| 47 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 0.7% | $43.5m | 2,186,636 | 0% | held |
| 48 | GERN GERON CORP | Healthcare | 0.7% | $42.5m | 30,126,299 | 0% | held |
| 49 | SATSUMA PHARMACEUTICALS INC | 0.7% | $41.7m | 5,914,252 | 0% | held | |
| 50 | LEGN LEGEND BIOTECH CORP | Healthcare | 0.6% | $40.1m | 977,503 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.